https://tissuepathology.com Educational and informative Fri, 15 May 2026 12:53:14 +0000 en-US hourly 1 https://tissuepathology.com/wp-content/uploads/2017/07/cropped-Portrait_640x960px-32x32.png https://tissuepathology.com 32 32 https://tissuepathology.com/2026/05/15/techcyte-announces-a-parasitology-validation-study-at-the-association-of-public-health-laboratories-conference-aphl/ Fri, 15 May 2026 12:53:14 +0000 https://tissuepathology.com/?p=24420 OREM, UT, UNITED STATES, May 4, 2026 /EINPresswire.com/ — Techcyte is pleased to announce that a validation study conducted by the Contra Costa County Public Health Laboratory (CCPHL) evaluating its AI-assisted ova and parasite (O&P) workflow has been accepted for presentation at the APHL 2026 Annual Conference. The poster will be made publicly available following the event on […]

The post Techcyte Announces a Parasitology Validation Study at the Association of Public Health Laboratories Conference (APHL) first appeared on Tissuepathology.com.]]> https://tissuepathology.com/2026/05/14/proscia-reflections-on-klas-us-digital-pathology-report-what-it-means-to-be-a-long-term-partner/ Thu, 14 May 2026 12:27:38 +0000 https://tissuepathology.com/?p=24416 From the Proscia blog: Going digital is a huge feat, and something well worth celebrating. But the labs seeing the biggest returns chose a platform that keeps compounding value long after go-live, scaling across departments and teams without friction, opening new revenue streams, and evolving alongside their ambitions. KLAS Research’s Digital Pathology 2026 report reinforces the importance of […]

The post Proscia: Reflections on KLAS’ US Digital Pathology Report: What it Means to Be a Long-Term Partner first appeared on Tissuepathology.com.]]> https://tissuepathology.com/2026/05/13/owkin-to-build-ai-agents-as-part-of-a-multi-year-k-pro-license-agreement-with-astrazeneca/ Wed, 13 May 2026 11:52:28 +0000 https://tissuepathology.com/?p=24414 Agreement includes a license for Owkin AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly analyze and forecast the competitive landscape for specific pharmaceutical targets, assets, and trials. NEW YORK & PARIS–(BUSINESS WIRE)–Owkin, the […]

The post Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca first appeared on Tissuepathology.com.]]> https://tissuepathology.com/2026/05/11/%f0%9d%90%91%f0%9d%90%a8%f0%9d%90%9c%f0%9d%90%a1%f0%9d%90%9e-%f0%9d%90%80%f0%9d%90%9c%f0%9d%90%aa%f0%9d%90%ae%f0%9d%90%a2%f0%9d%90%ab%f0%9d%90%9e%f0%9d%90%ac-%f0%9d%90%8f%f0%9d%90%9a%f0%9d%90%ad/ Mon, 11 May 2026 13:46:48 +0000 https://tissuepathology.com/?p=24407 Regarding the Roche acquisition of PathAI, from Elizabeth Bourn on LinkedIn: This morning, Roche announced that it had entered into a definitive merger agreement to acquire PathAI for $750M upfront, with up to $300M in additional milestone payments. Both vendors hope with this acquisition will scale the adoption of Digital Pathology, not only in routine […]

The post Roche Aquires PathAI: Implications for the Digital Pathology Market first appeared on Tissuepathology.com.]]> https://tissuepathology.com/2026/05/08/proscia-wins-2026-medtech-breakthrough-award-for-turning-the-moment-of-diagnosis-into-drug-development-insights/ Fri, 08 May 2026 12:42:25 +0000 https://tissuepathology.com/?p=24405 Proscia Honored alongside IQVIA, Medidata, and Thermo Fisher Scientific PHILADELPHIA — May 7, 2026 — Proscia®, a company bringing pathology to the center of precision medicine, has been named a winner in the 10th annual MedTech Breakthrough Awards, marking its second consecutive year of recognition. It was honored for enabling pharmaceutical companies to advance precision therapies […]

The post Proscia Wins 2026 MedTech Breakthrough Award for Turning the Moment of Diagnosis into Drug Development Insights first appeared on Tissuepathology.com.]]> https://tissuepathology.com/2026/05/07/roche-enters-into-a-definitive-merger-agreement-to-acquire-pathai-to-transform-ai-driven-diagnostics/ Thu, 07 May 2026 13:26:42 +0000 https://tissuepathology.com/?p=24403 PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche’s digital pathology portfolio to drive laboratory efficiency Combining Roche’s strong position in companion diagnostics and PathAI’s advanced AI platform helps accelerate clinical therapy development, foster the discovery of new biomarkers, and create novel diagnostic tools These integrated capabilities will […]

The post Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics first appeared on Tissuepathology.com.]]>